These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 36473902)

  • 1. The dynamics of extracellular DNA associates with treatment response in patients with rheumatoid arthritis.
    Macáková K; Illésová J; Mlynáriková V; Lesayová A; Konečná B; Vlková B; Celec P; Šteňová E
    Sci Rep; 2022 Dec; 12(1):21099. PubMed ID: 36473902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-cytokine therapy and plasma DNA in patients with rheumatoid arthritis.
    Lauková L; Konečná B; Vlková B; Mlynáriková V; Celec P; Šteňová E
    Rheumatol Int; 2018 Aug; 38(8):1449-1454. PubMed ID: 29796906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pre-Analytical Factors Affecting Extracellular DNA in Saliva.
    Janovičová Ľ; Holániová D; Vlková B; Celec P
    Diagnostics (Basel); 2024 Jan; 14(3):. PubMed ID: 38337765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sex Difference in Plasma Deoxyribonuclease Activity in Rats.
    Janovičová Ľ; Gromová B; Drobná D; Konečná B; Renczés E; Borbélyová V; Hodosy J; Celec P
    Physiol Res; 2021 Dec; 70(6):913-920. PubMed ID: 34717068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deoxyribonuclease activity negative correlates with extracellular DNA in uncomplicated singleton pregnancies in the third trimester.
    Vlková B; Janovičová Ľ; Pšenková P; Melníková L; Balažovjechová B; Záhumenský J; Celec P
    J Perinat Med; 2021 Jul; 49(6):755-758. PubMed ID: 33768760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-nuclear antibody development is associated with poor treatment response to biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis.
    Ishikawa Y; Hashimoto M; Ito H; Tanaka M; Yukawa N; Fujii T; Yamamoto W; Mimori T; Terao C
    Semin Arthritis Rheum; 2019 Oct; 49(2):204-210. PubMed ID: 30803720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating extracellular DNA is in association with continuous metabolic syndrome score in healthy adolescents.
    Celec P; Janovičová Ĺ; Gurecká R; Koborová I; Gardlík R; Šebeková K
    Physiol Genomics; 2021 Jul; 53(7):309-318. PubMed ID: 34097532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early Dynamics of Plasma Dna in a Mouse Model of Sepsis.
    Lauková L; Bertolo EMJ; Zelinková M; Borbélyová V; Čonka J; Gaál Kovalčíková A; Domonkos E; Vlková B; Celec P
    Shock; 2019 Aug; 52(2):257-263. PubMed ID: 30052582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No predictive effect of body mass index on clinical response in patients with rheumatoid arthritis after 24 weeks of biological disease-modifying antirheumatic drugs: a single-center study.
    Kim SK; Choe JY; Park SH; Lee H
    Clin Rheumatol; 2016 May; 35(5):1129-36. PubMed ID: 26932795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality of life and disease activity of patients with rheumatoid arthritis on tofacitinib and biologic disease-modifying antirheumatic drug therapies.
    Boyadzhieva V; Tachkov K; Stoilov N; Mitov K; Stoilov R; Petrova G
    Rheumatol Int; 2022 Oct; 42(10):1775-1783. PubMed ID: 35759028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessments of the unmet need in the management of patients with rheumatoid arthritis: analyses from the NOR-DMARD registry.
    Olsen IC; Lie E; Vasilescu R; Wallenstein G; Strengholt S; Kvien TK
    Rheumatology (Oxford); 2019 Mar; 58(3):481-491. PubMed ID: 30508189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial.
    Genovese MC; Kalunian K; Gottenberg JE; Mozaffarian N; Bartok B; Matzkies F; Gao J; Guo Y; Tasset C; Sundy JS; de Vlam K; Walker D; Takeuchi T
    JAMA; 2019 Jul; 322(4):315-325. PubMed ID: 31334793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dynamics of Plasma and Urinary Extracellular DNA in Acute Kidney Injury.
    Jančuška A; Potočárová A; Kovalčíková AG; Podracká Ľ; Bábíčková J; Celec P; Tóthová Ľ
    Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of abatacept tapering therapy for sustained remission in patients with rheumatoid arthritis: Prospective single-center study.
    Yoshida S; Kotani T; Kimura Y; Matsumura Y; Yoshikawa A; Tokai N; Ozaki T; Nagai K; Takeuchi T; Makino S; Arawaka S
    Int J Rheum Dis; 2019 Jan; 22(1):81-89. PubMed ID: 30168272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sex, Age, and Bodyweight as Determinants of Extracellular DNA in the Plasma of Mice: A Cross-Sectional Study.
    Janovičová Ľ; Konečná B; Vokálová L; Lauková L; Vlková B; Celec P
    Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31454899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extracellular DNA concentrations in various aetiologies of acute kidney injury.
    Gaál Kovalčíková A; Janovičová Ľ; Hodosy J; Bábíčková J; Vavrincová-Yaghi D; Vavrinec P; Boor P; Podracká Ľ; Šebeková K; Celec P; Tóthová Ľ
    Sci Rep; 2022 Oct; 12(1):16812. PubMed ID: 36207374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful discontinuation of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis in real-world settings.
    Ochiai M; Tanaka E; Sato E; Inoue E; Abe M; Saka K; Sugano E; Sugitani N; Higuchi Y; Yamaguchi R; Sugimoto N; Ikari K; Nakajima A; Yamanaka H; Harigai M
    Mod Rheumatol; 2021 Jul; 31(4):790-795. PubMed ID: 33538611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The longitudinal effect of biologic use on patient outcomes (disease activity, function, and disease severity) within a rheumatoid arthritis registry.
    Shadick NA; Gerlanc NM; Frits ML; Stolshek BS; Brady BL; Iannaccone C; Collier D; Cui J; Mutebi A; Weinblatt ME
    Clin Rheumatol; 2019 Nov; 38(11):3081-3092. PubMed ID: 31353421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors for low disease activity and remission in rheumatoid arthritis patients treated with biological DMARDs.
    Wacharapornin P; Suwannalai P
    J Med Assoc Thai; 2014 Nov; 97(11):1157-63. PubMed ID: 25675680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of healthcare resources in a cohort of rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs or tofacitinib.
    Machado-Alba JE; Machado-Duque ME; Gaviria-Mendoza A; Reyes JM; Gamboa NC
    Clin Rheumatol; 2021 Apr; 40(4):1273-1281. PubMed ID: 32997316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.